

STAT3 INHIBITORS ENHANCING IMMUNOTHERAPY AND TARGETING DRUG RESISTANCE

Advancing a pipeline of drug candidates against the highly promising target STAT3 for the treatment of advanced and drug resistant cancers, with encouraging pre-clinical in vivo data showing reduced tumor growth and metastatic spread and decreased immunosuppression

SALSS CONTACT

Martin Johansson
CEO

martin.johansson@glactone.com
+47 (076) 006 6029

Glactone Pharma Development AB
Kullagatan 8
SE-252 20 Helsingborg
Sweden

www.glactone.com

Founded in 2012, Glactone is a preclinical stage immuno-oncology drug company with a pipeline of small molecule inhibitors of STAT3, a highly sought-after cancer target that is activated in ~70% of solid and hematological tumors¹.

OUR PRODUCTS & SERVICES

Despite the transformative promise of immunotherapy, a majority of patients fail to achieve objective responses and most tumor regressions remain partial. A major unmet need therefore exists for novel therapies that can be combined with checkpoint inhibitors (PD-1/PD-L1). Prostate cancer, our primary indication, is the second leading cause of male cancer deaths in the USA and prognosis at the metastatic castration resistant prostate stage is extremely poor. By 2024 it is forecast to have the highest incidence of any cancer, with a market value of US\$13.8 billion, (>3x increase from 2014). Based on more than 15 years of academic research, Glactone's pipeline consists of three drug series targeting STAT3, a key transcription factor that is constitutively activated or over-expressed in many solid cancers, including prostate cancer. Inhibition results in reversal of immunosuppression and tumor proliferation. Glactone's STAT3 inhibitors have been shown to be effective in multiple cancer models, including inhibition of proliferation of enzalutamide resistant prostate cancer cells, reduced tumor growth and metastatic spread and reversal of immunosuppressive mechanisms. Our most promising series, GPB600, is being profiled in vivo, in combination with checkpoint blockade immunotherapy and in models of enzalutamide resistant prostate cancer².

WHAT MAKES US UNIQUE

Glactone has a highly experienced team with a focused strategy around STAT3. The company has strong IP with all rights fully owned and FTO analysis indicating freedom to operate commercially. STAT3 is very difficult drug target, requiring novel chemical space and approaches, so there are few competitors in this area.

WHY YOU SHOULD MEET US

The company plans to fund advancement of its promising pipeline of early-stage assets through the clinic and out-license after phase I, so the company is interested to speak to potential partners and investors.

KEY TEAM

- Martin Johansson, PhD
- Associate Prof. in organic chemistry; 15+ years medicinal chemistry & drug development
 - Former CSO, Respiratorius AB
 - Senior research scientist AstraZeneca, Medicinal Chemistry

BOARD

- Jan Törnell, MD, PhD
- Chairman
 - CEO of Oncorena; former VP in AstraZeneca Oncology & Infection; Prof. of Physiology, Gothenburg University,
- Jeanette Robertsson
PhD, MSc
- Jacob Kaluski, MSc,
(Pharm.)
- Olov Sterner, MSc, PhD
- Anders Bjartell, MD PhD

REFERENCES

- 1 Fagard R, Metelev V, Souissi I, Baran-Marszak F. STAT3 inhibitors for cancer therapy: Have all roads been explored? *JAK-STAT*. 2013;2(1):e22882. doi:10.4161/jkst.22882.
- 2 Zilma Escobar, Anders Bjartell, Giacomo Canesin, Susan Evans-Axelsson, Olov Sterner, Rebecka Hellsten, and Martin H Johansson, Preclinical Characterization of 3 β -(N-Acetyl L-cysteine methyl ester)-2a β ,3-dihydrogaliellalactone (GPA512), a Prodrug of a Direct STAT3 Inhibitor for the Treatment of Prostate Cancer, *Journal of Medicinal Chemistry* 2016 59 (10), 4551-4562

**SWEDISH
AMERICAN
LIFE SCIENCE
SUMMIT
2017**